Escizane (Tablets) Instructions for Use

Marketing Authorization Holder

Evalar, CJSC (Russia)

ATC Code

C05CX (Drugs reducing capillary permeability, other)

Active Substance

Aescine

Dosage Form

Escizane

Film-coated tablets, 110 mg: 20, 30, 40, or 60 pcs.

Dosage Form, Packaging, and Composition

30 pcs. – polymer bottles (1) – cardboard packs.
40 pcs. – polymer bottles (1) – cardboard packs.
60 pcs. – polymer bottles (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – contour cell blisters (1) – cardboard packs.
20 pcs. – contour cell blisters (2) – cardboard packs.
20 pcs. – contour cell blisters (3) – cardboard packs.

Clinical-Pharmacological Group

Herbal preparation, used for disorders of venous circulation

Pharmacotherapeutic Group

Venotonic agent of plant origin

Pharmacological Action

A triterpene glycoside (saponin) from horse chestnut fruit (seeds). It has a pronounced capillary-protective activity and exerts anti-exudative and venotonic effects.

It reduces the concentration of lysosomal enzymes, thereby decreasing the breakdown of mucopolysaccharides in the capillary wall area. It significantly reduces vascular permeability, preventing the filtration of low-molecular-weight proteins, electrolytes, and water into the intercellular space.

When applied topically, Aescine has an anti-inflammatory effect, mainly in the initial phase of the inflammatory reaction, by reducing the permeability of the capillary wall, which is increased during inflammation.

Aescine also has a positive effect on capillary wall fragility and increases the tone of venous walls when it is weakened. All this leads to a reduction in venous stasis and fluid accumulation in tissues, preventing the appearance of edema.

Pharmacokinetics

After oral administration of 50 mg of horse chestnut fruit extract, the C_max in blood plasma is reached after 2.35 hours and is 25.31 ng/ml.

Plasma protein binding is 84%.

T_1/2 is 19.87 hours. After oral administration, 0.11% of the horse chestnut fruit extract is excreted by the kidneys in the form of escin.

Indications

Post-thrombophlebitic syndrome and individual symptoms of chronic venous insufficiency of various etiologies (including edema, calf muscle cramps, pain and heaviness in the legs), varicose veins, trophic disorders. Post-traumatic or postoperative soft tissue edema.

ICD codes

Dosage Regimen

Administer orally or topically as appropriate for the clinical presentation.

For oral administration, take one 110 mg tablet three times daily with meals to enhance tolerability and absorption.

Continue the oral treatment course for a minimum duration of four weeks to achieve a stable therapeutic effect.

For topical application, gently rub the corresponding dosage form into the affected skin area several times per day until fully absorbed.

Adjust the total duration of therapy individually based on the severity of symptoms and clinical response.

Do not exceed the recommended oral dosage without medical supervision.

Discontinue use and consult a physician if symptoms persist or worsen after several weeks of treatment.

Adverse Reactions

Allergic reactions skin rash, urticaria, itching, redness, feeling of heat.

From the digestive system when taken orally – nausea, heartburn.

Contraindications

Hypersensitivity to escin.

Use in Pregnancy and Lactation

Oral administration during pregnancy, while breastfeeding, and in women of childbearing potential not using contraception is not recommended.

The necessity of topical application during pregnancy and breastfeeding is determined by the doctor individually.

Use in Renal Impairment

With long-term use, periodic monitoring of kidney function is recommended.

Pediatric Use

Use is possible according to the dosing regimen.

Special Precautions

Use topically with caution in patients prone to thrombosis.

Contraindications for oral preparations containing ethyl alcohol should be taken into account.

Drug Interactions

Concomitant use with escin may enhance the activity of anticoagulants and other drugs with antithrombotic action.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.